60
Participants
Start Date
January 31, 2013
Primary Completion Date
March 31, 2017
Study Completion Date
August 2, 2020
Bortezomib
1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
Cyclophosphamide
"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
Rituximab
Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
Fludarabine
Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
Basingstoke & North Hampshire Hospital, Basingstoke
Royal United Hospital, Bath
City Hospital, Birmingham
Pilgrim Hospital, Boston
Colchester General Hospital, Colchester
Darent Valley Hospital, Dartford
Dewsbury and District Hospital, Dewsbury
Royal Devon and Exeter Hospital, Exeter
Grantham and District Hospital, Grantham
Leicester Royal Infirmary, Leicester
Lincoln County Hospital, Lincoln
Royal Liverpool University Hospital, Liverpool
King's College Hospital, London
Northwick Park Hospital, London
Royal Free Hospital, London
Maidstone Hospital, Maidstone
Derriford Hospital, Plymouth
Pontefract Hospital, Pontefract
Queen's Hospital, Romford
Tunbridge Wells Hospital, Royal Tunbridge Wells
Salisbury District Hospital, Salisbury
Musgrove Park Hospital, Taunton
Torbay Hospital, Torquay
Pinderfields Hospital, Wakefield
Sandwell Hospital, West Bromwich
Royal Hampshire County Hospital, Winchester
Birmingham Heartlands Hospital, Birmingham
St James University Hospital, Leeds
St Bartolomew's Hospital, London
University College Hospital, London
University College, London
OTHER